公开(公告)号：US08101774B2

公开(公告)日：2012-01-24

申请号：US11250636

申请日：2005-10-17

申请人： Atsushi Hagiwara ,  Taku Ikenogami ,  Kazunori Kurihara ,  Toshio Taniguchi ,  Mitsuru Takahashi ,  Akio Iida

发明人： Atsushi Hagiwara ,  Taku Ikenogami ,  Kazunori Kurihara ,  Toshio Taniguchi ,  Mitsuru Takahashi ,  Akio Iida

IPC分类号： C07D213/56 ,  A61K31/44

CPC分类号： C07D295/192 ,  C07C237/42 ,  C07C255/55

摘要： The present invention relates to an ester represented by the formula [1]: or its pharmaceutically acceptable salt, or use of the same. The compound represented by the formula [1] or its pharmaceutically acceptable salt is useful as an agent for the treatment or prophylaxis of hyperlipidemia or the like, since it disappears very rapidly in the living body and has an excellent MTP inhibitory activity.

摘要翻译： 本发明涉及由式[1]表示的酯：或其药学上可接受的盐或其用途。 由式[1]表示的化合物或其药学上可接受的盐可用作治疗或预防高脂血症等的药剂，因为其在生物体中消失非常迅速，具有优异的MTP抑制活性。

公开(公告)号：US07807701B2

公开(公告)日：2010-10-05

申请号：US11939359

申请日：2007-11-13

申请人： Kimiya Maeda ,  Hironobu Nagamori ,  Hiroshi Nakamura ,  Hisashi Shinkai ,  Yasunori Suzuki ,  Daisuke Takahashi ,  Toshio Taniguchi

发明人： Kimiya Maeda ,  Hironobu Nagamori ,  Hiroshi Nakamura ,  Hisashi Shinkai ,  Yasunori Suzuki ,  Daisuke Takahashi ,  Toshio Taniguchi

IPC分类号： A61K31/41 ,  A61K31/42 ,  C07D257/04 ,  C07D263/30

CPC分类号： C07D213/74 ,  C07C229/46 ,  C07C255/58 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D231/38 ,  C07D239/42 ,  C07D249/14 ,  C07D257/06 ,  C07D261/14 ,  C07D263/48 ,  C07D271/07 ,  C07D271/10 ,  C07D275/02

摘要： A dibenzylamine compound represented by the formula (1) wherein R1 and R2 are each a C1-6 allyl group optionally substituted by halogen atoms and the like; R3, R4 and R5 are each a hydrogen atom, a halogen atom and the like, or R3 and R4 may form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring optionally having substituent(s); A is —N(R7)(R8) and the like; ring B is an aryl group or a heterocyclic residue; R6 is a hydrogen atom, a halogen atom, a nitro group, a C1-6 allyl group and the like; n is an integer of 1 to 3, a prodrug thereof and a pharmaceutically acceptable salt thereof show selective and potent CETP inhibitory activity, and therefore, they can be provided as therapeutic or prophylactic agents for hyperlipidemia or arteriosclerosis and the like.

摘要翻译： 由式（1）表示的二苄胺化合物，其中R 1和R 2各自为任选被卤素原子等取代的C 1-6烯丙基; R 3，R 4和R 5各自为氢原子，卤素原子等，或者R 3和R 4可以与其键合的碳原子一起形成任选具有取代基的双环或杂环; A是-N（R 7）（R 8）等; 环B是芳基或杂环残基; R6是氢原子，卤素原子，硝基，C1-6烯丙基等; n为1〜3的整数，其前药及其药学上可接受的盐具有选择性且有效的CETP抑制活性，因此可作为高脂血症或动脉硬化等的治疗剂或预防剂使用。

公开(公告)号：US07332514B2

公开(公告)日：2008-02-19

申请号：US10503185

申请日：2003-08-29

申请人： Kimiya Maeda ,  Hironobu Nagamori ,  Hiroshi Nakamura ,  Hisashi Shinkai ,  Yasunori Suzuki ,  Daisuke Takahashi ,  Toshio Taniguchi

发明人： Kimiya Maeda ,  Hironobu Nagamori ,  Hiroshi Nakamura ,  Hisashi Shinkai ,  Yasunori Suzuki ,  Daisuke Takahashi ,  Toshio Taniguchi

IPC分类号： A61K31/42 ,  A61K31/41 ,  C07D263/30 ,  C07D257/04

CPC分类号： C07D213/74 ,  C07C229/46 ,  C07C255/58 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D231/38 ,  C07D239/42 ,  C07D249/14 ,  C07D257/06 ,  C07D261/14 ,  C07D263/48 ,  C07D271/07 ,  C07D271/10 ,  C07D275/02

摘要： A dibenzylamine compound represented by the formula (1) wherein R1 and R2 are each a C1-6 alkyl group optionally substituted by halogen atoms and the like; R3, R4 and R5 are each a hydrogen atom, a halogen atom and the like, or R3 and R4 may form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring optionally having substituent(s); A is —N(R7) (R8) and the like; ring B is an aryl group or a heterocyclic residue; R6 is a hydrogen atom, a halogen atom, a nitro group, a C1-6 alkyl group and the like; n is an integer of 1 to 3, a prodrug thereof and a pharmaceutically acceptable salt thereof show selective and potent CETP inhibitory activity, and therefore, they can be provided as therapeutic or prophylactic agents for hyperlipidemia or arteriosclerosis and the like.

摘要翻译： 由式（1）表示的二苄胺化合物，其中R 1和R 2各自为任选被卤素取代的C 1-6烷基 原子等; R 3，R 4和R 5各自为氢原子，卤素原子等，或R 3， SUP>和R 4可以与其键合的碳原子一起形成任选具有取代基的杂环或杂环; A是-N（R 7）（R 8）等; 环B是芳基或杂环残基; R 6是氢原子，卤素原子，硝基，C 1-6烷基等; n为1〜3的整数，其前药及其药学上可接受的盐具有选择性且有效的CETP抑制活性，因此可作为高脂血症或动脉硬化等的治疗剂或预防剂使用。

公开(公告)号：US20070057328A1

公开(公告)日：2007-03-15

申请号：US11598808

申请日：2006-11-14

申请人： Toshio Taniguchi ,  Taiji Ema ,  Toru Anezaki

发明人： Toshio Taniguchi ,  Taiji Ema ,  Toru Anezaki

IPC分类号： H01L29/78 ,  H01L21/336

CPC分类号： H01L21/823814 ,  H01L21/823842 ,  H01L21/82385 ,  H01L21/823864 ,  H01L27/1052 ,  H01L27/10814 ,  H01L27/10873 ,  H01L27/10894 ,  H01L29/6659 ,  H01L29/7833

摘要： In a logic area, impurities are doped into the gate electrode and the source/drain diffusion regions of a MIS transistor. Thereafter in a memory cell area, word lines are patterned, source/drain regions are formed, and contact holes are formed. Side wall spacers of the MIS transistor in the logic area are made of silicon oxide. A semiconductor device of logic-memory can be manufactured by a reduced number of manufacture processes while the transistor characteristics are stabilized and the fine patterns in the memory cell are ensured.

公开(公告)号：US20060205726A1

公开(公告)日：2006-09-14

申请号：US11362375

申请日：2006-02-27

申请人： Atsushi Hagiwara ,  Taku Ikenogami ,  Yasuko Mera ,  Yukako Sumida ,  Akio Iida ,  Toshio Taniguchi ,  Mitsuru Takahashi

发明人： Atsushi Hagiwara ,  Taku Ikenogami ,  Yasuko Mera ,  Yukako Sumida ,  Akio Iida ,  Toshio Taniguchi ,  Mitsuru Takahashi

IPC分类号： A61K31/537 ,  A61K31/495 ,  A61K31/445

CPC分类号： C07D241/44 ,  C07C233/81 ,  C07D209/08 ,  C07D213/55 ,  C07D213/81 ,  C07D213/82 ,  C07D239/42 ,  C07D277/30 ,  C07D295/192 ,  C07D333/24 ,  C07D409/12 ,  C07D413/12

摘要： A therapeutic agent for hyperlipidemia which has no side effects on the liver unlike conventional MTP inhibitors and has excellent MTP inhibitory activity. Also, provided is an ester compound represented by the general formula (1): or a pharmaceutically acceptable salt thereof.

摘要翻译： 与常规MTP抑制剂不同，对肝脏没有副作用且具有优异的MTP抑制活性的高脂血症治疗剂。 此外，提供由通式（1）表示的酯化合物：或其药学上可接受的盐。

公开(公告)号：US07625948B2

公开(公告)日：2009-12-01

申请号：US10492831

申请日：2003-02-28

申请人： Atsushi Hagiwara ,  Yasuhiro Ohe ,  Naoya Odani ,  Shizue Watanabe ,  Taku Ikenogami ,  Takashi Kawai ,  Kenya Madono ,  Toshio Taniguchi

发明人： Atsushi Hagiwara ,  Yasuhiro Ohe ,  Naoya Odani ,  Shizue Watanabe ,  Taku Ikenogami ,  Takashi Kawai ,  Kenya Madono ,  Toshio Taniguchi

IPC分类号： A61K31/265 ,  A61K31/21 ,  A61K31/235 ,  C07C205/00 ,  C07C229/00 ,  C07C69/76

CPC分类号： C07D207/404 ,  A61K31/215 ,  A61K31/216 ,  A61K31/235 ,  A61K31/24 ,  A61K31/245 ,  A61K31/277 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/426 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/4453 ,  A61K31/4468 ,  A61K31/5375 ,  C07C69/732 ,  C07C69/76 ,  C07C69/88 ,  C07C233/81 ,  C07C235/06 ,  C07C235/14 ,  C07C235/16 ,  C07C235/26 ,  C07C235/30 ,  C07C235/34 ,  C07C235/40 ,  C07C235/64 ,  C07C235/84 ,  C07C237/42 ,  C07C311/04 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/18 ,  C07D205/12 ,  C07D207/09 ,  C07D207/16 ,  C07D209/08 ,  C07D211/58 ,  C07D213/55 ,  C07D213/61 ,  C07D213/82 ,  C07D235/06 ,  C07D263/58 ,  C07D277/30 ,  C07D277/56 ,  C07D295/135 ,  C07D295/192 ,  C07D333/24

摘要： A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1″) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6alkyl or C1-C6alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R8 and R9 are each independently hydrogen atom, C1-C6alkyl, —CON(R18)(R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.

摘要翻译： 作为高脂血症的新型治疗剂，其是由式（1“）表示的酯化合物（其中R 1和R 2各自为氢原子或任选取代的芳基等; X为-COO-或-CON（R 10） - ; R 3和R 4各自为氢原子，C 1 -C 6烷基或C 1 -C 6烷氧基等; R 5，R 6和R 7各自为氢原子，C 1 -C 6烷基或C 1 -C 6烷氧基等; R 8和R 9各自独立地为氢 原子，C 1 -C 6烷基，-CON（R 18）（R 19）或-COO（R 20）等;环A，环B和环C各自独立地为芳基或杂环残基等; Alk1和Alk2各自独立地为烷二基 等等; l和m各自为0或1至3的整数）或其前药，或其药学上可接受的盐。 治疗剂选择性地抑制小肠中的MTP，因此不会引起脂肪肝的副作用。

公开(公告)号：US20080146620A1

公开(公告)日：2008-06-19

申请号：US11939359

申请日：2007-11-13

申请人： Kimiya Maeda ,  Hironobu Nagamori ,  Hiroshi Nakamura ,  Hisashi Shinkai ,  Yasunori Suzuki ,  Daisuke Takahashi ,  Toshio Taniguchi

发明人： Kimiya Maeda ,  Hironobu Nagamori ,  Hiroshi Nakamura ,  Hisashi Shinkai ,  Yasunori Suzuki ,  Daisuke Takahashi ,  Toshio Taniguchi

IPC分类号： A61K31/4406 ,  C07C211/27 ,  A61K31/136 ,  C07D257/06 ,  A61K31/41 ,  A61P3/06 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61K31/4184 ,  C07D277/38 ,  A61K31/426 ,  C07D211/56

CPC分类号： C07D213/74 ,  C07C229/46 ,  C07C255/58 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D231/38 ,  C07D239/42 ,  C07D249/14 ,  C07D257/06 ,  C07D261/14 ,  C07D263/48 ,  C07D271/07 ,  C07D271/10 ,  C07D275/02

摘要： A dibenzylamine compound represented by the formula (1) wherein R1 and R2 are each a C1-6 allyl group optionally substituted by halogen atoms and the like; R3, R4 and R5 are each a hydrogen atom, a halogen atom and the like, or R3 and R4 may form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring optionally having substituent(s); A is —N(R7)(R8) and the like; ring B is an aryl group or a heterocyclic residue; R6 is a hydrogen atom, a halogen atom, a nitro group, a C1-6 allyl group and the like; n is an integer of 1 to 3, a prodrug thereof and a pharmaceutically acceptable salt thereof show selective and potent CETP inhibitory activity, and therefore, they can be provided as therapeutic or prophylactic agents for hyperlipidemia or arteriosclerosis and the like.

摘要翻译： 由式（1）表示的二苄胺化合物，其中R 1和R 2各自为任选被卤素取代的C 1-6 - 烯丙基 原子等; R 3，R 4和R 5各自为氢原子，卤素原子等，或R 3， SUP>和R 4可以与其键合的碳原子一起形成任选具有取代基的杂环或杂环; A是-N（R 7）（R 8）等; 环B是芳基或杂环残基; R 6是氢原子，卤素原子，硝基，C 1-6烯丙基等; n为1〜3的整数，其前药及其药学上可接受的盐具有选择性且有效的CETP抑制活性，因此可作为高脂血症或动脉硬化等的治疗剂或预防剂使用。

公开(公告)号：US20060158152A1

公开(公告)日：2006-07-20

申请号：US11333305

申请日：2006-01-18

申请人： Toshio Taniguchi ,  Toshio Matsubara

发明人： Toshio Taniguchi ,  Toshio Matsubara

IPC分类号： H02J7/00

CPC分类号： H02J7/025 ,  H02J50/12 ,  H04M1/7253

摘要： As the present invention is adapted to receive an image to be printed or to be saved from a portable device having the image by wireless communication, an image needs not to be passed via a memory card or by connector connection or the like. As the present invention is also adapted to automatically identify the other party's device to wirelessly communicate with and establish a channel, and further adapted to supply power to the other party's device without contact, it is advantageous that a battery of the portable device is not exhausted or the portable device is not disconnected even if the device communicates wirelessly for a long time.

公开(公告)号：US06775018B1

公开(公告)日：2004-08-10

申请号：US09712289

申请日：2000-11-15

申请人： Toshio Taniguchi

发明人： Toshio Taniguchi

IPC分类号： G06F1500

CPC分类号： H04N1/00925 ,  H04N1/00

摘要： A safety device for a printer has a first switch and a second switch that separately determines whether a door of the printer is open or closed. When the door is open (in the state that causes danger), the safety device stops driving systems of the printer with software when the second determining device determines that the door is open and stops the driving systems with hardware when the first determining device determines that door is open. Therefore, the safety device can completely stop the driving systems.

摘要翻译： 用于打印机的安全装置具有分开地确定打印机的门是打开还是关闭的第一开关和第二开关。 当门打开（导致危险的状态）时，当第二确定装置确定门打开时，安全装置停止使用软件的打印机的驱动系统，并且当第一确定装置确定为 门是开放的 因此，安全装置可以完全停止驱动系统。

公开(公告)号：US06522892B1

公开(公告)日：2003-02-18

申请号：US09040596

申请日：1998-03-18

申请人： Toshio Taniguchi

发明人： Toshio Taniguchi

IPC分类号： H04B140

CPC分类号： H04W52/50 ,  H04W52/228 ,  H04W52/325

摘要： In a radio, a signal is transmitted through a control channel or a call channel by use of one transmitting circuit, and the transmission output of the call channel is intentionally changed. At the time of transmission of a signal through the control channel, a closed loop is formed in order to feed back a detection output value of the transmission output of the control channel to a transmission output control section, thereby controlling the transmission output of the control channel. In contrast, at the time of transmission of a signal through the call channel, the closed loop is canceled, thereby controlling the transmission output of the call channel.

摘要翻译： 在无线电中，通过使用一个发送电路通过控制信道或呼叫信道发送信号，有意地改变呼叫信道的发送输出。 在通过控制信道发送信号时，形成闭环，以将控制信道的发送输出的检测输出值反馈到发送输出控制部，由此控制控制信号的发送输出 渠道。 相反，在通过呼叫信道发送信号时，闭环被取消，从而控制呼叫信道的发送输出。